(PTAB) paint a misleading picture, which is used to justify the agency’s budget requests but does a poor job of adequately portraying the effects of post-grant review proceedings on intellectual property owners.
Before law school, Vanessa was a Teach for America corps member in Oakland, California (1993-1996).
patent eligibility decisions, Fenwick & West has created the Patent Eligibility Case Analysis Tool, an interactive visual representation of this changing case law landscape.
Multiple petitioners will often gang up to challenge a single claim, which is why a patent-owning entity like while the PTAB can claim that the institution rate for IPR challenges on Zond’s patents was 88.6 percent.
If Zond experienced only an 88.6 institution rate how did they lose all 371 of the patent claims they owned?
Vanessa Power is Managing Partner of the firm’s Seattle office.
Vanessa is a litigator whose practice emphasizes complex business litigation.
This searchable tool provides short summaries of important post- patent eligibility decisions and the court’s rationale for each key finding.
Our list of decisions is not intended to be exhaustive.
A method for identifying an elevated myeloperoxidase (MPO) concentration in a plasma sample from a human subject with atherosclerotic cardiovascular disease comprising: a) contacting a sample with an anti-MPO antibody, wherein said sample is a plasma sample from a human subject having atherosclerotic cardiovascular disease; b) spectrophotometrically detecting MPO levels in said plasma sample; c) comparing said MPO levels in said plasma sample to a standard curve generated with known amounts of MPO to determine the MPO concentration in said sample; and d) comparing said MPO concentration in said plasma sample from said human subject to a control MPO concentration from apparently healthy human subjects, and identifying said MPO concentration in said plasma sample from said human subject as being elevated compared to said control MPO concentration. The method of claim 1, further comprising, prior to step a), centrifuging an anti-coagulated blood sample from said human subject to generate said plasma sample. § 101 as being directed to an unpatentable abstract idea.